Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) aims to strengthen its intellectual property (IP) portfolio with a provisional application for a new patent associated with the ADAPT® tissue technology.
If granted, the new patent, internally dubbed 'ADAPT® 2.0', will add to the current patent family as well as set new patent protections into the future for the ADAPT® process.
Notably, this application specifically augments particular aspects of the sterilisation process allowing the safe transfer of product to the manufacturer of heart valves.
“Ramp-up valve production”
Anteris CEO Wayne Paterson said “This new process opens up the potential for additional manufacturing sites for the company globally as volumes increase, as well as allowing the company to ramp up valve production (due to the extended shelf life before the manufacturing step).
"ADAPT® 2.0 will allow expanded manufacturing capacity of DurAVR™ at additional sites by starting the process in our Australian facility and completing valve manufacture at our US facility, saving significant time and money in the process.
“This is important as we enter the expanded clinical trial phase and for commercialization.”
About Anteris
Anteris Technologies is a structural heart company that is developing more durable solutions for a patient's heart health.
Its focus is on improving technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.
The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of its DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.